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Purpose: Improving the effectiveness of chemotherapeutic regimens has been a long- standing goal in
breast cancer therapy. In many cases, certain chemotherapeutic agents are combined to effectively treat
certain breast cancers. For instance, 5-fluorouracil (F), doxorubicin (A) and cyclophosphamide (C) are
combined together as the FAC regimen to treat various types of breast cancers. In this study, we explored
the effectiveness of this regimen in killing MDA MB 231 breast cancer cells with reduced G protein coupled
receptor kinases 2 (GRK2).
Methods: Triple negative MDA MB 231 breast cancer cells, with or without stable transfection with GRK2
shRNA to effectively decrease GRK2 protein expression, were treated with 5-fluorouracil (F), doxorubicin
(A) or cyclophosphamide (C) or all three combined for 72 hours. Thereafter, the extent of cell death was
evaluated using trypan blue exclusion. Changes in nuclear morphologies, an indicator for cell death, was
performed by staining the treated cells with dapi and visualized under fluorescent microscopy.
Results: MDA MB 231 breast cancer cells without GRK2 protein expression was more sensitive to
doxorubicin, as reported previously, and the FAC regimen. This effect was also observed timedependently and in experiments where doxorubicin concentrations were varied, from 10X less to 10X
more but with both 5-fluorouracil and cyclophosphamide concentrations kept constant. Preliminarily,
nuclear morphologies were similar in treated cells versus untreated cells when the cells were treated with
100X lower FAC concentrations.
Conclusion: In this study, we analyzed breast cancer cell death in order to better gauge the effectiveness
of various chemotherapeutic regimens. Based on these preliminary results, the FAC regimen appears to
be more effective in killing MDA MB 231 breast cancer cells without GRK2. This may imply that GRK2 may
be a biomarker to predict the effectiveness of FAC treatment, with potentially some breast cancers with
lower GRK2 expression levels showing more sensitivity to FAC compared to those with higher GRK2 levels.
This may also mean that inhibitors towards GRK2 may be beneficial combined with this particular regimen.

